Jasper Therapeutics (NASDAQ:JSPR - Get Free Report) is expected to be posting its Q1 2025 quarterly earnings results before the market opens on Tuesday, May 13th. Analysts expect the company to announce earnings of ($1.17) per share for the quarter.
Jasper Therapeutics (NASDAQ:JSPR - Get Free Report) last issued its earnings results on Thursday, February 27th. The company reported ($1.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.27) by ($0.35). On average, analysts expect Jasper Therapeutics to post $-4 EPS for the current fiscal year and $-5 EPS for the next fiscal year.
Jasper Therapeutics Stock Up 2.0 %
JSPR traded up $0.09 during mid-day trading on Friday, reaching $4.52. 129,296 shares of the company traded hands, compared to its average volume of 290,779. The stock has a market capitalization of $67.90 million, a P/E ratio of -0.95 and a beta of 2.74. Jasper Therapeutics has a 52-week low of $3.13 and a 52-week high of $26.84. The company's fifty day moving average price is $4.66 and its 200-day moving average price is $11.43.
Analysts Set New Price Targets
A number of research analysts recently issued reports on JSPR shares. HC Wainwright reiterated a "buy" rating and set a $40.00 price objective on shares of Jasper Therapeutics in a research note on Tuesday, March 11th. UBS Group initiated coverage on shares of Jasper Therapeutics in a report on Thursday, February 13th. They set a "buy" rating and a $38.00 price objective for the company. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $62.50.
Get Our Latest Report on JSPR
About Jasper Therapeutics
(
Get Free Report)
Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.
See Also

Before you consider Jasper Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Jasper Therapeutics wasn't on the list.
While Jasper Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.